
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.
Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
Astellas participates in Access Accelerated. Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving Non-Communicable Disease (NCD) care. Involving more than 20 biopharmaceutical companies, the initiative works with partners such as World Bank Group and the Union for International Cancer Control to help overcome a variety of access barriers to NCD medicines in low-income and lower-middle income countries. Access Accelerated will support multi-stakeholder dialogue and begin on-the-ground work to improve NCD prevention, diagnosis and treatment.
*This information describes Astellas’ support for the initiative as of January 18th, 2017
On May 15, 2018, Access Accelerated Year One Report was released, which introduces achievements in the first year of Access Accelerated. After its launch on January 18, 2017, 27 company access programs were launched or extended in 2017. Action on Fistula, a program to transform the lives of women in Kenya with fistula, is introduced in this report.
Access Accelerated Year One Report
Through participation in Access Accelerated, Astellas is helping to achieve the United Nations Sustainable Development Goal to reduce premature deaths from NCDs by one-third by 2030, in collaboration with various partners.